Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 19/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 19/20 | 0.51 |
| ▸ | NAE1 | Q13564 | 16/20 | 0.51 |
| ▸ | UBA3 | Q8TBC4 | 16/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18277514 | 0.97 | SAE1 (0.48) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL18277405 | 0.91 | SAE1 (0.46) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL18295059 | 0.90 | SAE1 (0.52) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL16388023 | 0.90 | SAE1 (0.66) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL18277084 | 0.82 | SAE1 (0.48) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL16388116 | 0.81 | SAE1 (0.51) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL19069918 | 0.81 | SAE1 (0.53) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL18277159 | 0.81 | SAE1 (0.48) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL18294938 | 0.80 | SAE1 (0.68) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL16388236 | 0.80 | SAE1 (0.75) | SAE1UBA2NAE1UBA3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016934-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355504-A1 | HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO2, SUMO1 | SAE1 1/4885UBA2 4/4885NAE1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.